PROTEINA
29.4.2024 06:18:35 CEST | Business Wire | Press release
PROTEINA announced today that it has held a kickoff meeting with Professor Janghee Woo and his research team at Emory University School of Medicine in Atlanta, to begin global clinical validation of its flagship product, PPI PathFinder BCL2 Dx.
PPI PathFinder BCL2 Dx incorporates PROTEINA’s “SPID (Single-molecule Protein Interaction Detection)” technology, enabling high-sensitivity detection of protein-protein interaction (PPI) complexes of BCL2 family proteins and more accurate prediction of any PPI inhibitors targeting the BCL2 family. In this clinical validation, PPI PathFinder BCL2 Dx will be used to predict drug responsiveness in patients with Acute Myeloid Leukemia (AML), providing clinicians with guidance for more effective prescriptions of the widespread BCL2-targeted cancer drug “Venetoclax.”
PROTEINA has previously conducted clinical validation of the same product domestically with the Hematologic Cancer Team at Seoul National University, and the findings are scheduled to be soon published in a high-profile scientific journal, Nature Biomedical Engineering, later this year.
Starting in May, PROTEINA will transport its Pi-View analysis device and related reagents to labs at Emory. Dr. Janghee Woo, a hematologist at Emory, has spearheaded a translational research laboratory focused on deciphering the molecular mechanisms underlying hematological malignancies to improve clinical outcomes. This endeavor entails the collection and examination of several hundred AML samples to investigate the molecular intricacies of the disease and pinpoint biomarkers linked to therapeutic response. PROTEINA and Dr. Woo’s research team will analyze these samples using the PPI PathFinder BCL2 Dx to validate its clinical efficacy.
Dr. Janghee Woo expressed optimism, stating, “This project will not only validate the clinical efficacy of the PPI PathFinder but also allow for collaboration across various fields through the expansion of solutions to further indications of Venetoclax.”
PROTEINA’s CEO, Tae-Young Yoon, remarked, “Having successfully completed domestic clinical validation in South Korea over the past two years, we are very excited about this large-scale clinical validation in the United States. We are committed to diligently completing the validation process as this would represent the first step towards wide use of PROTEINA SPID platform in providing PPI biomarkers for the emerging class of PPI-modulating drugs.”
Furthermore, through this project, PROTEINA aims to enhance the technological competitiveness of PPI PathFinder and the SPID platform and plans to supply the solution to overseas CLIA-certified labs based on the results of this exploratory clinical study.
About PROTEINA
Founded in 2015 in Seoul, PROTEINA is a leader in proteomics, enhancing drug research with its innovative Single-molecule Protein Interaction Detection (SPID) technology. This platform provides exceptional sensitivity for detecting protein-protein interactions, essential for pharmaceutical R&D. Serving top pharmaceutical companies and academic institutions worldwide, PROTEINA’s technology advances understanding of human biology, supporting modern healthcare solutions. With collaborations across Europe and North America, PROTEINA delivers insights that propel drug development and proteomic research.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240428101218/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brushing Well Is Harder Than Most People Think — New Research Confirms Why the Technology Behind Oral-B iO is the Best Way to Help You Get it Right17.9.2026 12:40:00 CEST | Press release
Ranked #1 for plaque removal and gingivitis reduction, Oral-B iO's oscillating-rotating technology, paired with its unique round brush head, delivers a superior clean that helps people brush better every day, remove more plaque, and improve their gum health for healthier teeth for life. Oral-B, the #1 toothbrush brand used and recommended by dentists worldwide, today announced new evidence reinforcing the superiority of Oral-B iO technology. In an independent 2026 peer-reviewed network meta-analysis of 19 randomized clinical studies involving more than 1,300 participants, the oscillating-rotating technology behind Oral-B iO was ranked #1 for plaque removal and gingivitis reduction. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260911054017/en/ Oral-B iO9 makes a superior clean easier to achieve every day. Most people think they are brushing effectively, but brushing well is harder than it seems. Plaque often remains in the
Former Colombian President Iván Duque Appointed to Advance ICC and Carbon Measures' Global Product-Level Carbon Accounting Initiative17.9.2026 12:00:00 CEST | Press release
Duque will chair the ICC & Carbon Measures Technical Expert Panel Advisory Group, bringing policy, business and practitioner perspectives into the next phase of their work. The International Chamber of Commerce (ICC) and Carbon Measures today announced that Iván Duque Márquez, former President of Colombia, has been named Chair of the newly created Technical Expert Panel Advisory Group established to complement the work of the TEP on Carbon Accounting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915635710/en/ The TEP, co-convened by ICC and Carbon Measures, brings together recognized experts from academia, financial accounting, industry and civil society to develop a globally applicable carbon emissions accounting framework. The TEP’s work comes amid growing global momentum toward harmonization of carbon accounting. The Advisory Group was created to take the TEP’s technical work to the next level, broadening engagement
Thales Unveils HexaForce: AI-Powered, Sovereign Command and Control for NATO and Allied Nations17.9.2026 12:00:00 CEST | Press release
Built on an open, interoperable architecture co-designed with armed forces, HexaForce was successfully tested during NATO CWIX 2026. HexaForce is tailored for high-intensity warfare, supporting command requirements for over 100,000 personnel where operational tempo requires the extensive, targeted deployment of AI. Thales’ multi-domain solution (covering land, sea, air, cyber, space, and information operations) is already available. Thales, a global leader in advanced technologies across Defence, Aerospace, and Cyber & Digital, has announced the launch of HexaForce, its next-generation AI-enhanced multi-domain command and control (C2) system. Purpose-built to support national sovereignty, HexaForce provides a rapid, battle-tested response to the massive growth in operational data and the accelerating pace of conflicts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260917956437/en/ HexaForce_2026©Thales “Some armed forces re
ABZ Innovation Opens One of Europe's Largest Civilian Drone Manufacturing Facilities17.9.2026 11:43:00 CEST | Press release
New facility in Szentendre, Hungary strengthens Europe's manufacturing capacity for agricultural and industrial drone technology ABZ Innovation, a European developer and manufacturer of heavy-duty civilian drones for agricultural and industrial use, today officially opened its new manufacturing facility in Szentendre, Hungary — one of the largest dedicated civilian drone production sites in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260917072041/en/ ABZ Innovation's new manufacturing facility in Hungary — one of the largest dedicated civilian drone production sites in Europe. The new facility is approximately four times larger than ABZ Innovation's previous production site, supporting a targeted threefold increase in production during 2026 alone, with a further doubling planned for 2027. This significantly expands ABZ Innovation's capacity to meet accelerating global demand for drone-based automation in agricultu
INSEAD Launches Immersive AI Cases as Its AI-Powered Learning Portfolio Passes 40 Experiences17.9.2026 11:00:00 CEST | Press release
INSEAD, The Business School for the World, today announced two milestones inAI-enabled learning: the commercial launch of its firstImmersive AI Cases via INSEAD Publishing and the expansion of its Immersive Learning portfolio to reach over 40 AI-powered learning experiences in the INSEAD classroom. Together, these developments mark an important milestone in INSEAD’s vision to translate AI-enabled learning into scalable educational offerings for educators and learners worldwide. They also demonstrate the growing adoption of immersive learning across the school and represent a key step in advancing the ambitions of IN:AI, INSEAD’s initiative to harness AI to transform business education and prepare leaders for an AI-enabled world. Francisco Veloso, Dean of INSEAD, said: “The future of management education will not be about choosing between human expertise and AI, but about bringing the two together in ways that deepen learning and strengthen judgement. We are putting this principle into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom